New investigation links common cholesterol drugs to kidney damage

2012-04-20 08:59

Older patients taking a class of cholesterol medicines known as fibrates may be at risk for kidney damage, finds a new investigation. Scientist at the Lawson Health Research Institute and the Institute for Clinical Evaluative Sciences (ICES), and colleagues, found that one in ten older patients who take the cholesterol drugs experience a 50% rise in their serum creatinine, which is a kidney function test. A serum creatinine test only rises when half of the kidney nephrons (filters) are damaged.

High cholesterol treatment with fibrates works primarily by lowering lipids (fats) in the blood stream known as triglycerides that could contribute to heart disease. The drugs do little to lower bad or LDL cholesterol levels. They work on the liver to reduce the number of triglycerides manufactured in the body as well as speeding the rate triglycerides are cleared from the bloodstream. If they are used long-term they can cause gallstones. Examples of the common cholesterol drugs include gemfibrozol (Lopid), and fenofibrate (TriCor, Triglide).

Cholesterol drugs may be of little value for heart health

ABC reported in March 2011 that the use of the drugs has steadily increased, despite hard evidence from clinical trials that they prevent heart attack or stroke.

"The use of fibrates in America is very troubling," said Dr. Steven E. Nissen, chairman of cardiovascular medicine at the Cleveland Clinic Foundation. Noting that fibrates are among medications advertised directly to consumers, he said: "This is a classical example of marketing triumphing over science”, ABC wrote.


Subscribe to EmaxHealth on YouTube